

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. A combined analysis of the LUX-Lung 3 and LUX-Lung 6 trials for patients with advanced EGFR mutation-positive lung adenocarcinoma demonstrated an overall survival advantage with afatinib for patients with \_\_\_\_\_.

  - a. Exon 19 deletion mutations
  - b. L858R mutations
  - c. Both a and b
2. A planned randomized Phase II trial by the Alliance Foundation will compare topotecan to \_\_\_\_\_ for patients with relapsed/refractory small cell lung cancer.

  - a. Nivolumab
  - b. Pembrolizumab
  - c. Ipilimumab
3. A Phase III trial evaluating nanoparticle albumin-bound (*nab*) paclitaxel/carboplatin versus solvent-based paclitaxel/carboplatin as first-line therapy for patients with advanced non-small cell lung cancer (NSCLC) demonstrated an increase in the incidence of \_\_\_\_\_ on the *nab* paclitaxel arm.

  - a. Thrombocytopenia
  - b. Anemia
  - c. Sensory neuropathy
  - d. All of the above
  - e. Both a and b
4. The combination of cisplatin and gemcitabine with necitumab demonstrated a clinical benefit in the first-line setting for patients with advanced NSCLC with \_\_\_\_\_ histology.

  - a. Squamous cell
  - b. Nonsquamous cell
  - c. Both a and b
5. A Phase III trial of second-line docetaxel with or without ramucirumab for patients with Stage IV NSCLC after disease progression on a platinum-based regimen demonstrated a statistically significant improvement in \_\_\_\_\_ with the addition of ramucirumab to docetaxel.

  - a. Median progression-free survival
  - b. Median overall survival
  - c. Overall response rate
  - d. Both a and c
  - e. All of the above
6. Results of a study evaluating cisplatin and pemetrexed with or without bevacizumab for patients with newly diagnosed pleural mesothelioma reported statistically significant improvement(s) in \_\_\_\_\_ with the addition of bevacizumab.

  - a. Median progression-free survival
  - b. Median overall survival
  - c. Both a and b
  - d. Neither a nor b
7. The novel antibody-drug conjugate rovalpituzumab tesirine being evaluated in relapsed/refractory small cell lung cancer \_\_\_\_\_.

  - a. Targets PD-1
  - b. Demonstrates activity as a single agent
  - c. Is associated with serositis
  - d. All of the above
  - e. Both b and c
8. Patients with advanced EGFR mutation-positive NSCLC treated with EGFR TKI therapy have a delay in the onset of brain metastases compared to those who receive chemotherapy.

  - a. True
  - b. False

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

9. Mutations in the MET exon 14 gene \_\_\_\_\_.

- a. Occur in about 3% of patients with nonsquamous NSCLC
- b. Are not sensitive to crizotinib
- c. May occur with concurrent MET amplification
- d. All of the above
- e. Both a and c

10. The checkpoint inhibitor pembrolizumab is approved for patients with squamous and nonsquamous NSCLC whose tumors are PD-L1-positive.

- a. True
- b. False